Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Bradley A. Schiff; Andrea B. McMurphy; Samar A. Jasser; Maher N. Youne; Dao Doan; Orhan G. Yigitbasi; Seungwon Kim; Ge Zhou; Mahitosh Mandal; Benjamin N. Bekele; FChristopher C. Holsinger; Steven I. Sherman; Sai Ching Yeung; Adel K. El-Naggar; Jeffrey N. Myers

ArticleOPEN ACCESS

Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Clinical Cancer Research

DOI: 10.1158/1078-0432.CCR-19-2052

1Citations

5Readers

Get full text

Abstract

The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.

Cite

CITATION STYLE

APA

Schiff, B. A., McMurphy, A. B., Jasser, S. A., Youne, M. N., Doan, D., Yigitbasi, O. G., … Myers, J. N. (2019, August 1). Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690). Clinical Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/1078-0432.CCR-19-2052

Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Abstract

Cite

Register to see more suggestions